SUBSCRIBE

Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

Read more breaking news

 

 

EFSA rejects 6 article 13.5 health claim opinions

By Shane Starling , 14-Feb-2013
Last updated on 15-Feb-2013 at 11:56 GMT2013-02-15T11:56:20Z

EFSA rejects 6 article 13.5 opinions

EFSA’s health claims panel has rejected 6 article 13.5 health claims for two digestion-focused probiotic submissions; cranberry and UTI; a potato extract and weight management; krill and menstrual discomfort; and fizzy water and GI response.

Potato extract

Kemin reacted strongly to EFSA’s Panel on Dietetic Products, Nutrition and Allergies (NDA) rejection of its potato extract’s (Slendesta) ability to assist weight loss. The Kemin dossier contained four unpublished human trials and a meta-analysis and the firm noted it had followed, similar statistical procedures to those considered to show a statistically significant effect on body weight loss in EFSA’s [positive] glucomannan opinion.”

That opinion can be found here .

“Kemin maintains a strong belief and confidence in the positive results of the clinical studies presented,” the firm continued.

“Kemin disagrees with the recent opinion issued by EFSA that a cause and effect relationship has not been established between the consumption of Slendesta and reduction of body weight.”

It added: Notably, EFSA’s negative opinion only addresses the proposed health claims that can be made on labeling of finished products in Europe and does not impact the ingredient’s regulatory status.”

“Slendesta retains its status as a lawful and non-novel food ingredient that can continue to be used by our customers in their food supplements and conventional foods.”

The claim targeted, “overweight adults wishing to lose weight”. The NDA said one study was uncontrolled while four others did not demonstrate an effect.

The Panel said the meta-analysis did not, “address the conditions of use proposed for the claim”.

Probiotics

French firm PiLeJe had two dossiers turned down, one for a probiotic blend rejected for lack of strain characterisation, a problem it failed to address when asked to by the NDA during a stop-the-clock procedure.

The ‘stool frequency’ blend contained Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102,Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104.

Click here for the opinion.

The other dossier was for intestinal discomfort using the same strains with the NDA highlighting the same concerns  over data.

Krill

The menstrual discomfort krill claim (EFAX) was submitted by Nutrilinks in the Netherlands. The NDA said a human intervention trial that showed positive results in breast tenderness, feeling overwhelmed, stress, irritability, depression, joint pain, weight gain, abdominal pain, swelling and bloating was, “insufficient to perform a full scientific evaluation”.

Cranberry

The Italian branch of Zambon submitted the cranberry-urinary tract infection (UTI) claim for its product Monurelle. The NDA referred to previous rejections of cranberry and said an ex-vivo study from Zambon did not alter its view of the berry and its extracts.

"The best way to confirm the in vitro experiments in vivo would be to develop a study design that would enable the direct observation of an anti-adhesive effect of cranberry on E. coli in situ," said Thomas Pauquai from the French conultancy, Nutraveris.

"But this may not be technically or ethically feasible and acceptable. It is not possible to observe the uroepithelial cells in situ in humans."

Fizzy water

Spanish company Vichy Catalan sought to link its carbonated natural mineral water and, “reduction of post-prandial triglyceride concentrations” among healthy adults. The NDA found supporting human studies had problems such as undefined endpoints and non-adjusted data in rejecting the claim.

Experts have condemned the dossiers for being flawed. See more on that here .

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Fytexia
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Indena
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Capsugel
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Ingredion
Balancing Innovation and Risk in Sports Nutrition Ingredients
NSF-International
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Roquette
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars